View Older Stories View More Recent Stories

Nov 14, 2022 08:02AM Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
Nov 4, 2022 04:05PM Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
Nov 4, 2022 04:05PM Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
Oct 31, 2022 09:00AM Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
Oct 31, 2022 09:00AM Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
Oct 27, 2022 08:00AM Sema4 (SMFR) Reports Strong Results from Phase 1 of SeqFirst Study
Oct 27, 2022 08:00AM Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
Oct 27, 2022 08:00AM Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
Oct 26, 2022 08:00AM Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
Oct 26, 2022 08:00AM Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
Oct 13, 2022 08:00AM Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
Oct 13, 2022 08:00AM Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
Oct 5, 2022 08:00AM Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study
Oct 5, 2022 08:00AM Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study
Aug 26, 2022 08:03AM Sema4 (SMFR) Appoints Kevin Feeley as CFO
Aug 26, 2022 08:00AM Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer
Aug 26, 2022 08:00AM Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer
Aug 15, 2022 04:05PM Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results
Aug 15, 2022 04:05PM Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results
Aug 15, 2022 04:05PM Sema4 Announces Changes to its Research & Development Leadership
Jul 26, 2022 08:00AM Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
Jul 26, 2022 08:00AM Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
Jun 14, 2022 04:53PM Sema4 (SMFR) CFO Isaac Ro to Resign, Richard Miao Named Interim CFO
Jun 14, 2022 04:30PM Sema4 Announces Chief Financial Officer Transition Plan
Jun 14, 2022 04:30PM Sema4 Announces Chief Financial Officer Transition Plan
Jun 1, 2022 08:30AM Avera Health and Sema4 Announce Data-driven Study to Advance Cancer Treatment Across the Avera Service Area
Jun 1, 2022 08:30AM Avera Health and Sema4 Announce Data-driven Study to Advance Cancer Treatment Across the Avera Service Area
May 26, 2022 08:00AM Sema4 to Participate at Two Investor Conferences in June 2022
May 26, 2022 08:00AM Sema4 to Participate at Two Investor Conferences in June 2022
May 12, 2022 04:05PM Sema4 Reports First Quarter 2022 Financial Results and Business Highlights
May 12, 2022 04:05PM Sema4 Reports First Quarter 2022 Financial Results and Business Highlights
May 4, 2022 04:05PM Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2022 04:05PM Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 2, 2022 07:45AM Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
May 2, 2022 07:45AM Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
Apr 26, 2022 04:05PM Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
Apr 26, 2022 04:05PM Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
Apr 6, 2022 08:00AM Sema4 Achieves HITRUST CSF Certification
Apr 6, 2022 08:00AM Sema4 Achieves HITRUST CSF Certification
Apr 5, 2022 08:00AM Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
Apr 5, 2022 08:00AM Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
Mar 16, 2022 08:00AM Sema4 Announces Nationwide Expansion of Disparity Study to Deliver Precision Oncology Care to Underserved Communities
Mar 16, 2022 08:00AM Sema4 Announces Nationwide Expansion of Disparity Study to Deliver Precision Oncology Care to Underserved Communities
Mar 14, 2022 04:05PM Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
Mar 14, 2022 04:05PM Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
Mar 8, 2022 08:00AM Sema4 Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022
Mar 8, 2022 08:00AM Sema4 Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022
Feb 22, 2022 04:05PM Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022
Feb 22, 2022 04:05PM Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022
Feb 22, 2022 08:00AM Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine
View More Recent Stories View Older Stories